Foster City, California-based Gilead Sciences, Inc. (GILD) discovers, develops, and commercializes medicines in the areas of ...

Gilead Sciences offers innovative drugs and boasts a 45,000% return since IPO, highlighting substantial growth. Investing in Gilead is accessible via brokerage accounts, using simple steps to buy ...

While the broader market has struggled with the S&P 500 down 2.4% since December 2024, Gilead Sciences has surged ahead as its stock price has climbed by 21% to $111.47 per share. This performance may ...

Despite a recent FDA clinical hold on its HIV treatment trials (GS-1720 and GS-4182) due to a decrease in CD4+ T-cells, Gilead Sciences (NASDAQ:GILD) has shown strong performance this year. Its stock ...

If you are wondering whether Gilead Sciences at US$134.36 is still offering value, the starting point is to understand what the current market price is implying about the business. The stock has ...

Gilead Sciences, Inc. (NASDAQ:GILD) will release earnings results for the second quarter, after the closing bell on Thursday, Aug. 7. Analysts expect the health care company to report quarterly ...

The market expects Gilead Sciences (GILD) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook ...

Looking ahead to 2030, our model projects GILD could trade at an average price of $236.30, with a potential range between $177.23 and $295.38. This represents a potential 84.5% return from today's ...